Drugplain

triCitrasol 14 g/30mL

Trisodium Citrate dihydrate · SOLUTION · Citra Labs LLC

No Recall History
Plain English

triCitrasol is a solution containing trisodium citrate dihydrate at 14 g/30mL, taken extracorporeal. Manufactured by Citra Labs LLC.

Key Facts

Brand Name
triCitrasol
Generic Name
Trisodium Citrate dihydrate
NDC Code (Product)
23731-6030
Manufacturer
Citra Labs LLC
Strength
14 g/30mL
Dosage Form
SOLUTION
Route
EXTRACORPOREAL
Marketing Status
Application #
BN010409
Marketing Start
07/10/2003

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

vomiting46 reports
ascites44 reports
condition aggravated37 reports
dyspnoea35 reports
off label use32 reports
abdominal distension29 reports
stress27 reports
abdominal pain26 reports
appendicitis26 reports
hyponatraemia26 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

INDICATIONS AND USAGE triCitrasol ® Anticoagulant Sodium Citrate Concentrate, 46.7% Trisodium Citrate, is an anticoagulant used in granulocytapheresis procedures (granulocyte collection by apheresis). Just prior to performing granulocytapheresis, aseptically add 30 mL of triCitrasol ® to 500 mL of the 6% solution of Hydroxyethyl Starch (HES), e.g. Hespan ® 2-8 . Agitate the resultant solution for 1 minute to assure a uniform concentration of anticoagulant. The resultant solution of triCitrasol ® and 6% solution of HES contains the following concentration depending upon the volume used: Volume of triCitrasol ® Volume of HES Total Volume Final Concentration of triCitrasol ® 30 mL 500 mL (measured from HES bag) 530 mL 2.6% 30 mL 558 mL (injected directly into HES bag) 588 mL 2.4% The triCitrasol ® /HES solution is stable for up to 24 hours at room temperature after mixing. Refer to the manufacturer's Operator's Manual of the apheresis medical device for the directions to perform the granulocytapheresis procedure.

Dosage & Administration

DOSAGE AND ADMINISTRATION The apheresis system will control the amount of the citrate/6% solution of HES that is added to the whole blood and the method of administration of the solution. Refer to the Operator's Manual of the apheresis medical device.

Warnings

WARNINGS CONCENTRATED ANTICOAGULANT – DILUTE PRIOR TO USE.

Contraindications

CONTRAINDICATIONS NOT FOR DIRECT INTRAVENOUS INFUSION.

Drug Interactions

Drug Interactions There are no adverse reactions for the addition of the product to the rouleaux agent.

Adverse Reactions

ADVERSE REACTIONS Citrate reactions or toxicity may occur with the infusion of blood products containing citrate anticoagulant 1. 9 11 . The recipient of the citrated blood product should be monitored for the signs and symptoms of citrate toxicity 1. 9 11 . The signs and symptoms of citrate toxicity begin with paresthesia, a "tingling" sensation around the mouth or in the extremities, followed by severe reactions that are characterized by chills, stomach cramps, or pressure in the chest, followed by more severe reactions that are characterized by hypotension and possible cardiac arrhythmia 1. 9 11 . Citrate toxicity may occur more frequently in patients that are hypothermic 10 , have impaired liver or renal function 10 , or have low calcium levels because of an underlying disease 9 .

Frequently Asked Questions

What is triCitrasol used for?

triCitrasol contains Trisodium Citrate dihydrate. It is a solution taken extracorporeal. Consult your doctor for specific uses.

Is triCitrasol a controlled substance?

triCitrasol is not classified as a controlled substance by the DEA.

What is the generic name for triCitrasol?

The generic name for triCitrasol is Trisodium Citrate dihydrate. There are 5 other brand versions of Trisodium Citrate dihydrate.

What is the NDC code for triCitrasol 14 g/30mL?

The NDC (National Drug Code) for triCitrasol 14 g/30mL is 23731-6030, listed by Citra Labs LLC.

Product NDC

23731-6030

Package NDC

23731-6030-1

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)